Приказ основних података о документу

dc.creatorFialova, Daniela
dc.creatorLaffon, Blanca
dc.creatorMarinković, Valentina
dc.creatorTasić, Ljiljana
dc.creatorDoro, Peter
dc.creatorSoos, Gyongyver
dc.creatorMota, Jorge
dc.creatorDogan, Soner
dc.creatorBrkić, Jovana
dc.creatorTeixeira, Joao Paulo
dc.creatorValdiglesias, Vanessa
dc.creatorCosta, Solange
dc.date.accessioned2019-09-02T12:11:39Z
dc.date.available2019-09-02T12:11:39Z
dc.date.issued2019
dc.identifier.issn0031-6970
dc.identifier.urihttps://farfar.pharmacy.bg.ac.rs/handle/123456789/3360
dc.description.abstractIntroductionThe importance of rational drug therapy is increasing with the aging of the population. Since one of the main reasons for inappropriate drug prescribing is also the age-blind approach, which results in ageist practices, this narrative literature review focuses on the description of the main barriers related to insufficient individualization of drug regimens associated with such age-blind approaches.MethodologyA narrative literature review using the PubMed, WoS, Embase, and Scopus databases was conducted by the EU COST Action IS1402. Experts in different scientific fields from six countries (the Czech Republic, Spain, Portugal, Hungary, Serbia, and Turkey) worked in four specific areas: (1) underrepresentation of older adults in clinical trials and clinical and ethical consequences; (2) insufficient consideration of age-related changes and geriatric frailty in the evaluation of the therapeutic value of drugs; (3) frequent prescribing of potentially inappropriate medications (PIMs); and (4) frequent underuse of highly beneficial nonpharmacological strategies (e.g., exercise).ResultsOlder patients are underrepresented in clinical trials. Therefore, rigorous observational geriatric research is needed in order to obtain evidence on the real efficacy and safety of frequently used drugs, and e.g. developed geriatric scales and frailty indexes for claims databases should help to stimulate such research. The use of PIMs, unfortunately, is still highly prevalent in Europe: 22.6% in community-dwelling older patients and 49.0% in institutionalized older adults. Specific tests to detect the majority of age-related pharmacological changes are usually not available in everyday clinical practice, which limits the estimation of drug risks and possibilities to individualize drug therapy in geriatric patients before drug prescription. Moreover, the role of somenonpharmacological strategies is highly underestimated in older adultsin contrast to frequent use of polypharmacy. Among nonpharmacological strategies, particularly physical exercise was highly effective in reducing functional decline, frailty, and the risk of falls in the majority of clinicalstudies.ConclusionSeveral regulatory and clinical barriers contribute to insufficient knowledge on the therapeutic value of drugs in older patients, age-blind approach, and inappropriate prescribing. New clinical and observational research is needed, including data on comprehensive geriatric assessment and frailty, to document the real efficacy and safety of frequently used medications.en
dc.publisherSpringer Heidelberg, Heidelberg
dc.relationEU COST Action IS 1402
dc.relationscientific program PROGRESS Q42 at the Department of Social and Clinical Pharmacy, Faculty of Pharma
dc.rightsopenAccess
dc.sourceEuropean Journal of Clinical Pharmacology
dc.subjectDrug prescribingen
dc.subjectOlder patientsen
dc.subjectAgeismen
dc.subjectFrailtyen
dc.subjectAge-related changesen
dc.subjectPotentially inappropriate medicationsen
dc.subjectPolypharmacyen
dc.subjectObservational studiesen
dc.subjectRandomized controlled trialsen
dc.titleMedication use in older patients and age-blind approach: narrative literature review (insufficient evidence on the efficacy and safety of drugs in older age, frequent use of PIMs and polypharmacy, and underuse of highly beneficial nonpharmacological straten
dc.typearticle
dc.rights.licenseARR
dcterms.abstractФиалова, Даниела; Теиxеира, Јоао Пауло; Лаффон, Бланца; Тасић, Љиљана; Цоста, Соланге; Валдиглесиас, Ванесса; Маринковић, Валентина; Бркић, Јована; Доган, Сонер; Доро, Петер; Мота, Јорге; Соос, Гyонгyвер;
dc.citation.volume75
dc.citation.issue4
dc.citation.spage451
dc.citation.epage466
dc.citation.other75(4): 451-466
dc.citation.rankM22
dc.identifier.wos000462155900002
dc.identifier.doi10.1007/s00228-018-2603-5
dc.identifier.pmid30610276
dc.identifier.scopus2-s2.0-85059689400
dc.identifier.fulltexthttps://farfar.pharmacy.bg.ac.rs//bitstream/id/1921/3358.pdf
dc.type.versionpublishedVersion


Документи

Thumbnail

Овај документ се појављује у следећим колекцијама

Приказ основних података о документу